Just a few possible drivers of SP growth - mostly from the recent quarterly report.
- MLA expanded sales & marketing team to continue recent OEM healthcare supply agreements
- They commented they were currently in negotiation on further tenders - a bit of a 'who knows when' comment, but could be a big driver if they secure a couple chunky deals, espec given margins of around 50%
- Rights issue, plumped up the account by around 2million.. acquisition? as groberts noted, appointment of CFO
- Further cost reductions, a few one offs in last year's reporting, centralised location & rebound of Clements and core businesses etc
- Medivet: Success with nanofiber, settlement against vet stem and validation by Uni of Kentucky. Recruitment of sales staff in USA & Australia combined and Delk appointed to the board, might lead to an uptake in US procedure numbers?
- Pie funds taking a stake & Lang Walker (billionaire) topping up in the recent rights issue. Ian Mitchell taking full rights entitlement and topping up on market back in July at around 15c.
MLA Price at posting:
6.6¢ Sentiment: Buy Disclosure: Held
